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Summary requisite to the understanding of the dysfunctional regu-
lation in the fragile X patient. A ﬁrst deﬁnition of the
Fragile X syndrome is associated with silencing of the
5 FMR1 regulatory region was obtained on the basis
FMR1 gene. We studied the transcriptional regulation,
of reporter-gene analysis (Hwu et al. 1993) and from a
by analysis of the FMR1 promoter region for the pres-
transgenic-model system (Hegersberg et al. 1995). Pro-
ence of in vivo protein/DNA interactions and for cyto-
teins binding to synthetic CGG repeat sequences were
sine methylation at the single-nucleotide level. Four pro-
detected and were characterized, by in vitro gel-shift
tein-binding sites were present in the unmethylated
assays (Richards et al. 1993), but the functional rele-
promoter of the active FMR1 gene. In the methylated
vance of these ﬁndings is not clear. Data on methylation
promoter of inactive genes no footprints were detected,
of the FMR1 promoter still are limited, since only single
and no evidence of active repression was found in the
recognition sites of methylation-sensitive restriction en-
region investigated. We propose that the silencing of
donucleases have been analyzed (Bell et al. 1991; Oberle´
FMR1 gene transcription results from a lack of tran-
et al. 1991; Pieretti et al. 1991; Vincent et al. 1991;
scription-factor binding.
Hansen et al. 1992; Sutcliffe et al. 1992; Richards et al.
1993). Thus, an interpretation of the methylation status
Introduction of the complete promoter region is not possible. Previous
methylation analysis at the single-nucleotide level con-
The transcriptional activity of a gene is regulated by
cerned the repeat itself and its surrounding region but
numerous transacting protein factors that interact with
included only a small segment of the promoter (Hornstra
speciﬁc cis-acting elements (La Thangue and Rigby
et al. 1993).
1988; Wasylyk 1988; Latchman 1991). Changes in
The aim of the present work was to study the tran-
these interactions occur during the transition from an
scriptional regulation of the FMR1 gene and the interfer-
inactive to an active state and often are accompanied
ences in regulation by mutation and/or by methylation,
by alterations in cytosine methylation (Ehrlich and
in the intact living cell. Therefore, we characterized the
Ehrlich 1993; Graessmann and Graessmann 1993).
in vivo interaction of transcription factors with the
Therefore, methylation of control regions in the ge-
FMR1 promoter and evaluated the DNA methylation
nome is thought to play a critical role in the regulation
of the corresponding region. Our data demonstrate the
of gene expression.
involvement of methylation in the process of FMR1 gene
In fragile X syndrome, full expansion of the FMR1
regulation. Footprinting analysis of the methylated pro-
CGG repeat usually is associated with methylation and
moter suggests that gene silencing is characterized by
gene inactivation (Bell et al. 1991; Oberle´ et al. 1991;
lack of protein binding.
Pieretti et al. 1991; Verkerk et al. 1991; Sutcliffe et al.
1992; Verheij et al. 1993). Since this phenomenon is
found in affected individuals only, hypermethylation of Material and Methods
the FMR1 CpG island may represent an alteration of
Cell Linesnormal regulation. Analysis of the active gene is a pre-
Human ﬁbroblast cell lines were established from skin
biopsies taken from adult normal males, transmitting
males, and fragile X patients. Embryonic cell lines wereReceived June 26, 1996; accepted for publication March 19, 1997.
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Southern Blot Analysis and Reverse Transcriptase–PCR the linker, and 3 units of Taq polymerase [Perkin Elmer
Cetus]). Samples were covered with mineral oil, and(RT-PCR) Analysis
PCR was performed. After initial denaturation at 95CGenomic DNA was extracted from cultured cells, was
for 3 min, the samples were denatured at 95C for 1cleaved with restriction endonuclease EagI, EcoRI, or
min, were annealed at 66C (all the different primers IIPstI (New England Biolabs), was separated on 0.8%
that were used worked at this temperature), and wereagarose gels, was blotted onto Hybond N/ membranes,
extended at 76C for 3 min. With each cycle the exten-and was hybridized with DNA probe Ox1.9 or Ox0.55
sion time was increased for 5 s. After 20 cycles, the(Nakahori et al. 1991). Probes were radiolabeled by use
sample was incubated at 76C, and 5 ml of booster solu-of the random-priming method (Feinberg and Vogelstein
tion (containing diluted Taq-polymerase mix plus 1 unit1983). Poly(A)/ RNA was puriﬁed by oligo(dT) cellu-
of fresh Taq polymerase per sample) was added. Afterlose chromatography, was transcribed into cDNA, and
10 min of incubation, samples were placed on ice, andsubsequently was ampliﬁed by use of primers 4924
1–5 pmol of end-labeled primer III, 2.5 units of Taqand 4925 (for FMR1) and primers 243 and 244 (for
polymerase, and 20 nmol of each dNTP were added.the hypoxanthine guanine phosphoribosyltransferase
After initial denaturation at 94C for 3 min, samples[HPRT] gene), according to the protocol described in
were cycled twice as follows: 94C for 1 min; 69C–the study by Pieretti et al. (1991). Aliquots of the PCR
72C, depending on the melting temperature of primerreaction were added to a loading-dye mix and were
III, for 2 min; and 76C for 10 min. Then, polymeraseelectrophoresed in an 80-V constant ﬁeld, in 2%
activity was stopped, and the samples were extractedagarose gels.
with phenol/chloroform, were precipitated, and were re-
Genomic Sequencing of DNA by Ligation-Mediated suspended in loading dye. Half the reaction was sepa-
PCR (LMPCR) rated on a sequencing gel and was visualized by autora-
diography. The control reactions were done with theGenomic DNA was isolated according to standard
procedures. After cleavage with EcoRI, aliquots of cloned 5.2-kb EcoRI fragment of the FMR1 gene
(Nakahori et al. 1991). For analysis of the upper25–50 mg of DNA were subjected to Maxam-Gilbert
sequencing reactions. Chemical sequencing was per- DNA strand, three primer sets, A, B, and C, were used.
These sets included the following sequences: AI,formed as described in the study by Pfeifer and Riggs
(1993), and LMPCR was performed according to the 5-CGCCCGCTCAGAGGC-3; AII, 5 CAGAGG-
CGGCCCTCCACCGGAA-3; AIII, 5-AGTGAA-protocol described in the studies by Mueller and Wold
(1989) and Pfeifer et al. (1989). For ﬁrst-strand synthesis ACCGAAACGGAGCTGAGCGCCT -3  ; BI ,
5-ACCGAAACGGAGCTGAG-3; BII, 5-GAGCTG-with Sequenase, 3 mg of cleaved genomic DNA, 0.3 pmol
of primer I, and 3 ml of 51 Sequenase buffer were mixed, AGCGCCTGACTAGGGCCGAA-3; BIII, 5-ACC-
ACGTCACGTGATCAACGCTGTTCCCTC3; CI,and water was added, bringing the total volume to 15
ml. Denaturation at 95C for 5 min was followed by 5-TCTCTCTTCAAGTGGCCTGG-3; CII, 5-GCA-
TGCGCGCTGCTGGGAACC-3; and CIII, 5-CCG-primer annealing at 45C for 30 min. Then the probes
were cooled on ice, and 7.5 ml of a freshly prepared Mg- GGGTGCCGGGTCGAAAGACAGACG-3. For analy-
sis of the lower strand, primer sets D, E, and F weredNTP mix (20 mM of MgCl2, 20 mM of DTT, and
0.25 mM of each dNTP) and 1.5 ml of a 1:4 dilution of used. These sets included the following sequences: DI,
5  -GAATCCCAGAGAGGCCGAACTG-3  ; DII,Sequenase (version 2; United States Biochemical) were
added. The mixture was incubated at 46C for 15 min. 5-GGCCGAACTGGGATAACCGGATGCA-3; DIII,
5  -GGATGCATTTGATTTCCCACGCCACTG-After the reaction was stopped (by cooling, the addition
of 6 ml of 310 mM Tris-HCl [pH 7.7], and incubation AGTG-3; EI, 5-CCGCCCTCCACCAAG-3; EII,
5-CGCGTCTGTCTTTCGACCCGGCA-3; EIII,at 67C for 15 min), 45 ml of freshly prepared ligation
mix (13 mM of MgCl2, 30 mM of DTT, 1.7 mM of 5-GGCCGGTTCCCAGCAGCGCGCATG-3; FI,
5-TCAGTGTTTACACCCGCAGC-3; FII, 5-CCT-ATP, 80 mg of BSA/ml, and 100 pmol of linker/reaction)
and 3 Weiss units of T4 DNA ligase (Promega) were AGTCAGGCGCTCAGCTCCGTTTC-3; and FIII,
5-CAGCTCCGTTTCGGTTTCACTTCCGGTGG-3.added. Tubes were incubated overnight at 17C. After
ligation, the reaction was stopped by heating of the mix-
In Vivo Dimethyl Sulfate (DMS)–Footprinting Analysisture to 70C for 10 min, and the samples were precipi-
tated with 10 mg of carrier tRNA. For PCR ampliﬁca- The cultured cells were washed twice with PBS and
subsequently were treated with 0.1% DMS in serum-tion, the sample was suspended in 50 ml of water, and
50 ml of Taq-polymerase mix was added (ﬁnal concen- free DMEM medium for 8 min at room temperature.
Then, the DMS-containing medium was removedtrations in a 100-ml PCR reaction were as follows: 1
1 Taq buffer, 2 mM of MgCl2, 0.25 mM of dNTP, 10 quickly, and the cells were washed with ice-cold PBS.
Subsequently, DNA was extracted by standard proce-pmol of primer II, 10 pmol of the longer oligomer of
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dures, was treated with piperidine, and, ﬁnally, was sub-
jected to LMPCR as described above.
Results
In Vivo Protein-Binding Studies
Analysis of in vivo protein/DNA interaction was
performed by use of DMS footprinting by ligation-
mediated PCR (Mueller and Wold 1989; Pfeifer et al.
1989). Adult human ﬁbroblast cell lines and a fetal
ﬁbroblast cell line were investigated. All cell lines were
characterized for a fragile X mutation, by Southern
blot analysis, and for the transcriptional activity of
the genes FMR1 and HPRT, by RT-PCR, as illustrated
in ﬁgures 1 and 2, respectively. The lines were derived
from adult male controls (ﬁg. 1a and b, lanes 2 and
3), from two transmitting males—one showing
expansions in the pre- and full-mutation ranges, with
partial methylation of the largely expanded fragments
at the EagI restriction site (ﬁg. 1a and b, lane 5), and
the other presenting only an unmethylated premuta-
tion (ﬁg. 1a and b, lane 4)—from two adult full-muta-
tion males (ﬁg. 1a and b, lanes 7 and 8), and from
one male fetus (ﬁg. 1, lane 6) with largely expanded
and methylated fragments. Analysis of the cell lines is
summarized in table 1.
In order to deﬁne the promoter and upstream-pro-
moter elements of the FMR1 gene, we investigated the
300 nucleotides upstream of the cap site, for the pres-
ence of in vivo protein/DNA interactions. In the normal
FMR1 gene, four footprints, designated ‘‘I,’’ ‘‘II,’’ ‘‘III,’’
and ‘‘IV’’ (ﬁg. 3), were present. The positions of the
protein-binding sites are given in ﬁgure 4. The position
numbers of ﬁgure 4 correspond to ﬁle HSFXDNA of
GenBank (accession X61378), which contains the se-
Figure 1 Southern blot analysis of DNA samples from a controlquence originally reported in the study by Fu et al. female and from normal, transmitting, and full-mutation males, di-
(1991). Site I is close to the presumed TATA box–like gested with PstI (a) and EcoRI / EagI (b). The ﬁlters were hybridized
sequence element (Hwu et al. 1993) and shows a palin- with probes Ox0.55 (a) and Ox1.9 (b). Lane 1, Control female with
fragments within the normal size range (a) and with a methylateddromic sequence motif. In this palindrome, two G resi-
inactive X (5.2-kb band) and an unmethylated active X (2.8-kb band),dues are protected on either strand. The sequences of
at the EagI site (b). Lanes 2 and 3, Normal males with unmethylatedthe protein-binding site are 5-CACGTG-3 and 3- fragments of normal size. Lanes 4 and 5, Transmitting males. Lane
GTGCAC-5, with the protected G’s indicated by un- 6, Embryonic cell line from a male fetus, showing a full mutation.
derlining. Lanes 7 and 8, Cell lines from adult full-mutation males.
The second protein-binding site, 5-GGGGGAGG-3,
shows protection of a cluster of six adjacent guanosines
(positions 2517–2521 and 2523) at the upper DNA 3 end on the opposite DNA strand could be deﬁned.
With repeated experiments, a region of approximatelystrand. A potential binding site for the transcription fac-
tor Sp1 is given with footprint III, showing the consensus eight bases adjacent to the boundaries of this footprint
appeared very faint on one DNA strand and thus didsequence 5-GGGCGG-3 at the upper strand (positions
2490–2495). The most upstream-located and also not permit evaluation of the degree of protection of
the G residues. This also is true for the other Maxam-palindromic cis-acting element shows protected G resi-
dues on both DNA strands. The sequences are 5- Gilbert base-speciﬁc control reactions (G, G/A, C/T,
and C). Therefore, although located within or near aGCGCATGCGC-3 and 3-CGCGTACGCG-5. In this
case, the exact 5 boundaries of protection could not be protein-binding site, this phenomenon cannot be due
to protein binding. A similar observation of the 5identiﬁed on either strand. However, the corresponding
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Footprinting data of the two transmitting males
who were investigated showed some individual differ-
ences. One of these nonretarded males was typical in
that he presented, on PstI and EcoRI / EagI digests,
restriction fragments in only the premutation size
range and no evidence of EagI-site methylation (ﬁg.
1a and b, lane 4). This male showed protein/DNA
interactions representing the same binding patternFigure 2 RT-PCR products from normal males (lanes 1 and 2),
that was seen in the normal FMR1 gene (ﬁg. 5, lanefrom carriers (lanes 3 and 4), and from fragile X patients (lanes 5 and
3). The other transmitting male presented a complex6, adult tissue; lane 7, fetal tissue). The larger band (387 bp) corre-
sponds to the ampliﬁcation product of the HPRT gene. The smaller somatic mosaic consisting of repeats with length vari-
band (146 bp) corresponds to ampliﬁcation of the FMR1 transcript. ation reaching from the premutation range to the full-
mutation range. EagI site–methylation analysis of this
male revealed that probably the majority of expan-
ﬂanking region upstream of the CGG repeat has been sions were unmethylated (ﬁg. 1a and b, lane 5). In this
described by Hornstra et al. (1993), who discussed particular case, footprint data were not that clear and
methodical problems and particular structural alter- may represent incomplete protection.
ations in this gene region as possible causes. No indi- Footprints were absent in the full-mutation males—
cations of further protein/DNA interaction were de- two adults and one fragile X fetus—who were investi-
tected in our analysis of the neighboring upstream gated (ﬁg. 3, lanes 3 and 4; ﬁg. 5, lanes 1 and 2). In
DNA region. A scheme summarizing the footprinting these cases, RT-PCR conﬁrmed the absence of FMR1
transcripts.data is presented in ﬁgure 4.
Table 1




MUTATION FMR1 GENE EagI-Site Genomic IN VIVO
PATIENT AND SAMPLE RANGEa EXPRESSIONb Analysis Sequencing FOOTPRINTS
Male fragile X fetus:
Fibroblast cell line Full 0 / / 0
Fragile X male:
Fibroblast cell line Full 0 / / 0
Fragile X male:
Fibroblast cell line Full 0 / /c 0
Transmitting male:d
Fibroblast cell line Pre/full / 0// No data /
Transmitting male:
Fibroblast cell line Pre / 0 0 /
Normal male:
Fibroblast cell line . . . / 0 0 /
Normal male:
Fibroblast cell line . . . / 0 0 /
Fragile X male:e
Different tissues Full 0 / No data No data
Tissue of lung tumor Pre / / / No data
NOTE.—A plus sign (/) indicates the presence of gene expression, methylation, and/or in vivo footprints;
and a minus sign (0) indicates the absence of gene expression, methylation, and/or in vivo footprints.
a Data from Southern blot analysis.
b Transcriptional activity assayed by RT-PCR.
c Most CpG dinucleotides were methylated, and single CpGs remained unmethylated.
d Presented with a mosaic pattern of pre- and fully mutated, methylated and unmethylated fragments.
e Mutation, expression (FMR1 protein detection by immunohistochemistry), andEagI and BssHII methyla-
tion data according to Smeets et al. (1995); note that only native tissues (no cell lines) were investigated.
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Figure 4 Sequence of the investigated promoter region of the
FMR1 gene. The position numbers correspond to sequence ﬁle
HSFXDNA of GenBank (accession X61378). The sites of protein pro-
tection, footprints I, II, III, and IV, are indicated by boxes (crossed-
out G’s denote protected G residues and boldface G’s denote visible
G residues). The exact 5 boundaries (indicated by dotted lines) of
footprint IV could not be determined on either strand. The TATA-
like box (position 2558–2563) described in the study by Hwu et al.
(1993) is indicated by a dotted line, and the putative transcription
start site is indicated by an arrow.
methylation status of the FMR1 control region. Geno-
mic DNA from normal males, transmitting males, and
affected males (from adult as well as from fetal tissues)
was subjected to methylation analysis. The cytosine-spe-
ciﬁc sequencing lanes of normal males and normal trans-
mitting males (ﬁg. 6, lane 4) displayed a continuous
Figure 3 In vivo DMS footprinting of the upper DNA strand
of the FMR1 promoter region. Lanes 1 (G/A) and 2 (G), Control
reactions of naked DNA. Lane 3, Fibroblast cell line of an adult fragile
X patient. Lane 4, Fibroblast cell line of a fetus with full mutation.
Lane 5, Fibroblast cell line of a normal male. Lane 6, Cell line of
another phenotypically normal male. The positions of the footprints
(lanes 5 and 6) are indicated by vertical bars, and the corresponding
sequences are shown to the right of each bar (a minus sign [0] denotes
a protected G residue and a plus sign [/] denotes a visible G residue).
Primer set A was used.
DNA Methylation Analysis
With methylation analysis by LMPCR-aided genomic
Figure 5 In vivo DMS footprinting of the FMR1 promoter re-sequencing, the methylation status of each individual
gion of the upper DNA strand, including footprint III (bottom) andcytosine residue can be deﬁned. Compared with unmeth-
footprint IV (top). G0 Å protected G residues; G Å visible G residues;ylated control samples (plasmid-cloned DNA containing
and (G) Å G residues located in the region of faint bands. Lane 1,
the region of interest), methylated cytosines result in Fibroblast cell line of an adult fragile X patient. Lane 2, Fibroblast
the absence of single bands within the cytosine-speciﬁc cell line of a fetus with full mutation. Lanes 3 and 4, Fibroblast cell
lines of two normal males. Primer set B was used.sequencing ladder. We primarily were interested in the
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affected male (ﬁg. 6, lane 3) revealed a combination of
methylated and unmethylated CpG residues. Interest-
ingly, during proliferation of this cell line, changes were
observed in both the mutation and the methylation pat-
tern, which is a phenomenon that is investigated further.
The methylation data of the investigated FMR1 pro-
moter region are summarized in ﬁgure 7.
Data on methylation and expression of the FMR1
gene in neoplastic tissue were ﬁrst reported in a male
fragile X patient with lung cancer (De Graaff et al.
1995). The premutated FMR1 gene of this patient was
expressed in the tumor tissue instead of methylation at
the EagI and BssHII sites. Since methylation at these
two sites does not necessarily imply methylation of the
complete promoter region, we studied the entire region
by genomic sequencing, using the DNA sample origi-
nally isolated from the same piece of tumor tissue that
was characterized previously by Southern blot analysis
and by immunohistochemistry. We had to restrict our
investigation to methylation analysis of the upper DNA
strand, because of the limited amount of tumor DNA
available. All CpG dinucleotides were methylated (ﬁg.
6, lanes 1 and 2).
Discussion
The phenotype of fragile X syndrome is assumed to
be caused by absence of the FMR1 protein. A large
Figure 6 Genomic sequencing and methylation analysis of part
of the FMR1 promoter region (nucleotide positions 2502–2565). The
methylation state of ﬁve CpGs (indicated by blackened circles) in the
C tracks of different genomic DNA samples are shown (lanes 1–4).
Lanes 1 and 2, Lung tumor of a male fragile X patient. Lane 3,
Fibroblast cells of a male with full mutation, showing both methylated
and unmethylated CpGs. Lane 4, Fibroblast cells of a normal transmit-
ting male. Unblackened circles indicate other C residues. Vertical lines
to the right of the sequence indicate footprint I (bottom) and footprint
II (top). Primer set A was used.
ladder of single bands. This holds true for the entire
Figure 7 Summary of DNA cytosine-methylation data of theregion that was investigated and for both the upper and
investigated FMR1 region (nucleotides 2270–2681). The positionlower DNA strands, suggesting that all CpGs were un-
numbers correspond to sequence ﬁle HSFXDNA of GenBank (acces-
methylated in these phenotypically normal males. In two sion X61378). Shaded C’s indicate methylated CpG sites detected in
fragile X patients, there was an absence of signals in all the adult patients and in the fetus with full mutation. Boxed C’s
indicate CpG sites that could not be analyzed because of their localiza-5-CG-3 dinucleotide positions of the FMR1 promoter
tion in the so-called faint region surrounding footprint IV. An asteriskon either DNA strand, suggesting the presence of meth-
(*) indicates methylated CpG sites, as previously described in the studyylcytosine residues in all 5-CG-3 positions. No differ-
by Hornstra et al. (1993). The boxed area (nucleotides 2301–2590)
ence in the methylation pattern was detected between indicates nucleotides for which methylation analysis of both DNA
the DNA samples from the adult and the fetal fragile X strands was performed. S Å SacII restriction site; B Å BssHII restric-
tion site; and E Å EagI restriction site.patients. However, a ﬁbroblast cell line of one adult,
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majority of affected individuals show large expansions of the FMR1 promoter region in males is restricted to
full-mutation alleles. In two full-mutation patients, thereof the CGG repeat, methylation of the CpG island, and
a lack of FMR1 transcripts (Bell et al. 1991; Oberle´ et was evidence for methylation of each individual CpG
that was investigated. However, single CpG sites wereal. 1991; Steinbach et al. 1993). This indicates that the
major control point for the lack of gene expression lies not methylated in another patient with full mutation.
Some of these unmethylated CpGs were located withinat the level of transcriptional regulation. Therefore, we
have studied methylation and in vivo protein binding in a deﬁned in vivo protein-binding site. This partial lack
of methylation obviously did not allow either for normalthe FMR1 promoter.
Promoter activity previously has been assigned to the protein binding or for transcriptional activity. Further
genomic-sequencing analysis of partially methylatedDNA segment 5 to the CGG repeat, by CAT (chloram-
phenicol acetyltransferase gene) assay and transient gene FMR1 promoters will help to detect common patterns
of methylation and to identify those sites of CpGmethyl-expression (Hwu et al. 1993; Hegersberg et al. 1995).
Nuclear proteins have been found to bind synthetic ation that are functionally relevant. The fact that meth-
ylation is associated with full mutations and with inacti-p(CGG)n oligonucleotides and a 430-bp DNA fragment
of the CpG island containing 30 CGG repeats (Richards vation of the FMR1 gene already has been known, and
our data do not change this perception. We report thatet al. 1993; Zhong et al. 1995), but the functional rele-
vance of these ﬁndings remained unclear. We detected the absence of transcription-factor binding in the investi-
gated promoter region of inactive genes could be relatedfour actual protein-binding sites in the FMR1 promoter,
using the in vivo–footprinting technique. These protein/ to methylation. The restriction sites of BssHII, EagI, and
SacII are located either within (BssHII) or immediatelyDNA interactions were found in transcriptionally active
genes of normal individuals and were absent from inac- adjacent to (EagI and SacII) regulatory element IV. They
frequently are used in diagnostic methylation ap-tive genes of affected males. Hence, the binding sites
represent cis-regulatory elements of the FMR1 pro- proaches but may not always be representative for the
complete promoter.moter, and their sequences now can be used to identify
the corresponding transcription factors. The DNA seg- In normal somatic cells, protein/DNA interaction at
the identiﬁed regulatory elements was shown to be sensi-ments covered by the four observed footprints could be
identiﬁed in transcription-factor databases. An imper- tive to methylation, since there were no in vivo foot-
prints detectable in the methylated promoter regions.fect Sp1-binding motif is identiﬁed in site II, followed
by a perfect Sp1 consensus site (footprint III). Control Thus, the repression of FMR1 transcription in fragile
X syndrome and the inhibition of transcription-factorelement I in the FMR1 promoter presented the palin-
dromic sequence CACGTG, which is a potential binding binding probably are related to DNA methylation.
There were no alternative footprints found in the meth-site for transcription factor c-myc (Ariga et al. 1989;
Blackwell et al. 1990; Blackwood and Eisenman 1991; ylated promoter region that was investigated. Repres-
sion, therefore, probably does not result from bindingDang et al. 1991). Binding site IV could be occupied by
alpha pal or by Nrf1 (Jacob et al. 1989; Chan et al. of a particular repressor protein to the methylated se-
quences that were investigated here. Missing footprints1993a, 1993b). There have been only limited data on
in vitro gel-shift experiments with DNA fragments that in the methylated promoter might indicate methylation
sensitivity of single, critical, or even most transcriptioninclude the four in vivo–deﬁned binding sites. In a pub-
lished abstract, Zhong et al. (1995) reported in vitro factors involved in the regulation of FMR1 gene tran-
scription. A possible exception is Sp1, which is knownbinding of transcription factors Sp1, Ap1, and CREB.
As shown by our in vivo–footprinting experiments, to be methylation insensitive (Harrington et al. 1988;
Ho¨ller et al. 1988).however, only the binding of Sp1, most probably to
the perfect consensus sequence GGGCGG (site III), is FMR1 gene regulation in the lung tumor could be
different from the situation in the normal, nontrans-functionally relevant. Preliminary data from our own
gel-shift experiments suggest that the imperfect Sp1- formed cell. Despite methylation at the EagI and BssHII
sites, gene expression was detected in the tumor, con-binding motif is not used by Sp1 (data not shown). A
CREB consensus-sequence motif (TGACGT) is located taining a premutation of the FMR1 gene (De Graaff et
al. 1995). Our genomic-sequencing data seem to supportadjacent to element I but did not contribute to the pro-
tein-binding pattern at this site. The same holds true for the evidence that this promoter is completely methyl-
ated, but we cannot be absolutely sure that our methyla-the Ap1-binding motif.
With genomic sequencing, we have analyzed DNA tion data do represent the tumor cells expressing the
premutated FMR1 gene. Since no culture of lung-tumormethylation of the CpG-rich promoter region, bridging
the gap between the single, upstream-located restriction- cells was available, footprint analysis could not be done
and further questions concerning FMR1 gene regulationenzyme recognition sites and the immediately adjacent
repeat area. Our data seem to conﬁrm that methylation in this methylated tissue could not be addressed. Methyl-
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De Graaff E, Willemsen R, Zhong N, de Die-Smulders CEM,ation insensitive isoforms or different sets of transacting
Brown WT, Freling G, Oostra B (1995) Instability of theproteins may be involved in transcriptional regulation
CGG repeat and expression of the FMR1 protein in a malein the transformed lung cells. The transcriptional activ-
fragile X patient with a lung tumor. Am J Hum Genet 57:ity of certain protein factors could be increased in tumor
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